» Articles » PMID: 8831080

Dexamethasone Associated Systemic Hypertension in Low Birth Weight Babies with Chronic Lung Disease

Overview
Journal Eur J Pediatr
Specialty Pediatrics
Date 1996 Jul 1
PMID 8831080
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: To assess the role of dexamethasone treatment as a cause of systemic hypertension and associated complications, blood pressure was registered prospectively before, during and after a 4-week dexamethasone course in 22 neonates with chronic lung disease. In all patients systolic blood pressure rose significantly during treatment (median rise 34 mm Hg, range 4-->59 mm Hg), without complications attributable to hypertension. In all but one patient blood pressure returned to pretreatment values within 2 weeks after stopping dexamethasone treatment.

Conclusion: Dexamethasone induced hypertension is transient, even after a 4-week course, and is not associated with hypertensive complications, so treatment is not necessary. When hypertension persists after dexamethasone withdrawal other causes should be considered.

Citing Articles

Cardiovascular Sequelae of Bronchopulmonary Dysplasia in Preterm Neonates Born before 32 Weeks of Gestational Age: Impact of Associated Pulmonary and Systemic Hypertension.

Pharande P, Sehgal A, Menahem S J Cardiovasc Dev Dis. 2024; 11(8).

PMID: 39195141 PMC: 11354795. DOI: 10.3390/jcdd11080233.


The effectiveness of dexamethasone as a combination therapy for COVID-19.

Namazi N Acta Pharm. 2023; 72(3):345-358.

PMID: 36651541 DOI: 10.2478/acph-2022-0030.


Neonatal hypertension: concerns within and beyond the neonatal intensive care unit.

Altemose K, Dionne J Clin Exp Pediatr. 2022; 65(8):367-376.

PMID: 35638239 PMC: 9348950. DOI: 10.3345/cep.2022.00486.


Potential Adverse Effects of Dexamethasone Therapy on COVID-19 Patients: Review and Recommendations.

Chen F, Hao L, Zhu S, Yang X, Shi W, Zheng K Infect Dis Ther. 2021; 10(4):1907-1931.

PMID: 34296386 PMC: 8298044. DOI: 10.1007/s40121-021-00500-z.


Neonatal hypertension: an educational review.

Harer M, Kent A Pediatr Nephrol. 2018; 34(6):1009-1018.

PMID: 29974208 DOI: 10.1007/s00467-018-3996-1.


References
1.
Greenough A, Emery E, Gamsu H . Dexamethasone and hypertension in preterm infants. Eur J Pediatr. 1992; 151(2):134-5. DOI: 10.1007/BF01958959. View

2.
Abman S, Warady B, Lum G, Koops B . Systemic hypertension in infants with bronchopulmonary dysplasia. J Pediatr. 1984; 104(6):928-31. DOI: 10.1016/s0022-3476(84)80501-6. View

3.
Hawkins K, Watson A, Rutter N . Neonatal hypertension and cardiac failure. Eur J Pediatr. 1995; 154(2):148-9. DOI: 10.1007/BF01991920. View

4.
Werner J, Sicard R, Hansen T, Solomon E, Cowett R, Oh W . Hypertrophic cardiomyopathy associated with dexamethasone therapy for bronchopulmonary dysplasia. J Pediatr. 1992; 120(2 Pt 1):286-91. DOI: 10.1016/s0022-3476(05)80446-9. View

5.
Perlman J, Moore V, Siegel M, Dawson J . Is chloride depletion an important contributing cause of death in infants with bronchopulmonary dysplasia?. Pediatrics. 1986; 77(2):212-6. View